Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
100 participants
INTERVENTIONAL
2015-10-31
2019-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Preoperative Portal and Splanchnic Flow Measurement Using MRI
NCT03868397
Evaluation of Hepatic Fibrosis on Multiparametric MRI
NCT03085342
MRI in Portal Hypertension
NCT01756859
Variations of Portal Flow During the Respiratory Cycle in Healthy Volunteers
NCT04782531
Magnetic Resonance Imaging in the Evaluation of Liver Fibrosis
NCT01572064
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Pressure gradient measurement portosystemic
* MRI measurement of azygos flow, aortic, portals, spleen and lower cellar
* Liver biopsy
* Laboratory tests
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention
The measurement of portosystemic pressure gradient will be performed before liver biopsy.
Then liver biopsy is performed. The MRI was performed on the day of biopsy or within one week around the completion of the biopsy.
The MRI machine used is the Siemens 3T.
Intervention
All patients performing the biopsy will have an MRI to carry out the necessary measures.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Intervention
All patients performing the biopsy will have an MRI to carry out the necessary measures.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Indication to perform a liver biopsy transjugular
* Patient able to consent
Exclusion Criteria
* Holders of a pacemaker or a defibrillator, an implanted material activated by electrical, magnetic or mechanical
* Holders of hemostatic clips intracerebral aneurysms or carotid arteries, bearing orthopedic implants
* claustrophobic
* Severe hepatic encephalopathy
* Inability to MRI in the week surrounding the first jugular
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Toulouse
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Phillipe OTAL, MD
Role: PRINCIPAL_INVESTIGATOR
UH TOULOUSE
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UH Toulouse
Toulouse, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008 Mar 8;371(9615):838-51. doi: 10.1016/S0140-6736(08)60383-9.
Garcia-Pagan JC, De Gottardi A, Bosch J. Review article: the modern management of portal hypertension--primary and secondary prophylaxis of variceal bleeding in cirrhotic patients. Aliment Pharmacol Ther. 2008 Jul;28(2):178-86. doi: 10.1111/j.1365-2036.2008.03729.x. Epub 2008 May 2.
Bosch J, Abraldes JG, Berzigotti A, Garcia-Pagan JC. The clinical use of HVPG measurements in chronic liver disease. Nat Rev Gastroenterol Hepatol. 2009 Oct;6(10):573-82. doi: 10.1038/nrgastro.2009.149. Epub 2009 Sep 1.
Thabut D, Moreau R, Lebrec D. Noninvasive assessment of portal hypertension in patients with cirrhosis. Hepatology. 2011 Feb;53(2):683-94. doi: 10.1002/hep.24129.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
University Hospital Toulouse
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
RC31/14/7318
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.